NCT05035381 2021-09-05
PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
Tianjin Medical University Cancer Institute and Hospital
National Cancer Centre, Singapore
Shanghai JMT-Bio Inc.
SuZhou Stainwei Biotech Inc.